A U.S. District Court judge overturned a jury verdict Aug. 28 that upheld several Amgen patents for its cholesterol reducing drug Repatha. The court found that Thousand Oaks-based Amgen’s patents did not adequately describe the product, called a PCSK9 inhibitor, which is an antibody that binds to an enzyme to reduce a particular kind of…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
